THE IMPACT OF PHARMACOKINETICALLY GUIDED DOSE ESCALATION STRATEGIES IN PHASE-I CLINICAL-TRIALS - CRITICAL-EVALUATION AND RECOMMENDATIONS FOR FUTURE STUDIES

被引：40
|
作者：
GRAHAM, MA
WORKMAN, P
机构：
[1] CRC Department Medical Oncology, University of Glasgow, CRC Beatson Laboratories, Bearsden, Glasgow
来源：
ANNALS OF ONCOLOGY | 1992年 / 3卷 / 05期
关键词：
PHARMACOKINETIC STRATEGIES; PHASE-I TRIALS; DOSE ESCALATION;
D O I：
10.1093/oxfordjournals.annonc.a058203
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Phase I studies requiring multiple dose escalation steps have led to the development of pharmacokinetically guided dose escalation (PGDE) strategies to expedite the conduct of early clinical trials. This article critically reviews PGDE strategies for a number of new anticancer agents including amphethinile, brequinar sodium, iodo-doxorubicin, the anthrapyrazoles (DuP 941, DuP 942 and DuP 937), rhizoxin, and aphidicolin glycinate. The benefits and problems associated with PGDE are examined. Recommendations are made for the optimal deployment of pharmacological information in future phase I studies.
引用
收藏
页码：339 / 347
页数：9
相关论文
共 21 条
  • [1] PHARMACOKINETICALLY GUIDED DOSE ESCALATION IN PHASE-I CLINICAL-TRIALS - COMMENTARY AND PROPOSED GUIDELINES
    NEWELL, DR
    EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1987, 23 (07): : 1083 - 1087
  • [2] PRECLINICAL AND PHASE-I STUDIES WITH RHIZOXIN TO APPLY A PHARMACOKINETICALLY GUIDED DOSE-ESCALATION SCHEME
    GRAHAM, MA
    BISSETT, D
    SETANOIANS, A
    HAMILTON, T
    KERR, DJ
    HENRAR, R
    KAYE, SB
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1992, 84 (07): : 494 - 500
  • [3] PHASE-I STUDY OF THE ANTHRAPYRAZOLE CI-941 WITH PHARMACOKINETICALLY GUIDED DOSE ESCALATION
    GRAHAM, MA
    FOSTER, BJ
    NEWELL, DR
    GUMBRELL, LA
    CALVERT, AH
    BRITISH JOURNAL OF CANCER, 1988, 58 (02) : 258 - 258
  • [4] A NOVEL STRATEGY FOR DOSE ESCALATION IN PHASE-I CLINICAL-TRIALS OF CHEMOTHERAPEUTIC-AGENTS
    SMITH, DB
    EWEN, C
    BRITISH JOURNAL OF CANCER, 1987, 56 (02) : 214 - 214
  • [5] PHASE-I TRIAL OF THE ANTHRAPYRAZOLE CI-941 - PROSPECTIVE EVALUATION OF A PHARMACOKINETICALLY GUIDED DOSE-ESCALATION
    FOSTER, BJ
    NEWELL, DR
    GRAHAM, MA
    GUMBRELL, LA
    JENNS, KE
    KAYE, SB
    CALVERT, AH
    EUROPEAN JOURNAL OF CANCER, 1992, 28A (2-3) : 463 - 469
  • [6] COMBINATION CLINICAL-TRIALS WITH THYMIDINE AND FLUOROURACIL - A PHASE-I AND CLINICAL PHARMACOLOGIC EVALUATION
    WOODCOCK, TM
    MARTIN, DS
    DAMIN, LAM
    KEMENY, NE
    YOUNG, CW
    CANCER, 1980, 45 (05) : 1135 - 1143
  • [7] MODEL-GUIDED DETERMINATION OF MAXIMUM TOLERATED DOSE IN PHASE-I CLINICAL-TRIALS - EVIDENCE FOR INCREASED PRECISION
    MICK, R
    RATAIN, MJ
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (03) : 217 - 223
  • [8] PHARMACOLOGICALLY GUIDED PHASE-I CLINICAL-TRIALS BASED UPON PRECLINICAL DRUG DEVELOPMENT
    COLLINS, JM
    GRIESHABER, CK
    CHABNER, BA
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1990, 82 (16): : 1321 - 1326
  • [9] THE IMPACT OF PHASE-I CLINICAL-TRIALS ON THE QUALITY-OF-LIFE OF PATIENTS WITH CANCER
    MELINK, TJ
    CLARK, GM
    VONHOFF, DD
    ANTI-CANCER DRUGS, 1992, 3 (06) : 571 - 576
  • [10] CT-GUIDED LASER THERAPY IN RESISTANT HUMAN-TUMORS - PHASE-I CLINICAL-TRIALS
    GATENBY, RA
    HARTZ, WH
    ENGSTROM, PF
    ROSENBLUM, JS
    HAMMOND, ND
    KESSLER, HB
    MOLDOFSKY, PJ
    CLAIR, MR
    UNGER, E
    BRODER, GJ
    RADIOLOGY, 1987, 163 (01) : 172 - 175
123